AbstractThe N-terminal region of the human papillomavirus (HPV) L2 protein has been shown to contain immune epitopes able to induce the production of neutralizing and cross-neutralizing antibodies (Gambhira et al., 2007; Kawana et al., 1999). Using bacterial thioredoxin as a scaffold, we managed to enhance the immunogenicity of putative L2 neutralizing epitopes, but only a minor fraction of the resulting immune responses was found to be neutralizing (Rubio et al., 2009). To determine the recognition patterns for non-neutralizing, neutralizing and cross-neutralizing antibodies, we isolated and characterized a panel of 46 monoclonal antibodies directed against different HPV16 L2 epitopes. Four of such antibodies proved to be neutralizing, and...
The minor capsid protein L2 is a promising candidate for the construction of an anti-human papilloma...
Background: Virus-like Particles (VLPs) display can be used to increase the immunogenicity of hetero...
The currently available nonavalent human papillomavirus (HPV) vaccine exploits the highly antigenic ...
AbstractThe N-terminal region of the human papillomavirus (HPV) L2 protein has been shown to contain...
Human papillomavirus (HPV) capsids are composed of 72 pentamers of the major ...
AbstractAntisera induced by immunization of rabbits with the synthetic peptide P56/75, which has the...
Background: Human papillomavirus (HPV) capsids are composed of 72 pentamers of the major capsid prot...
AbstractNeutralizing antibody against human papillomavirus (HPV) minor capsid protein L2 can cross-n...
Background: Current vaccines against HPVs are constituted of L1 protein self-assembled into virus-li...
Both the Human papillomavirus (HPV) major (L1) and minor (L2) capsid proteins have been well investi...
Abstract Background Current vaccines against HPVs are constituted of L1 protein self-assembled into ...
Abstract Vaccination of mice with minor capsid protein L2 or passive transfer with the L2-specific n...
AbstractCryoelectron microscopy images of HPV16 pseudovirions (PsV) depict that each pentamer of L1 ...
International audienceBACKGROUND: Current vaccines against HPVs are constituted of L1 protein self-a...
Virus-like Particles (VLPs) display can be used to increase the immunogenicity of heterologous antig...
The minor capsid protein L2 is a promising candidate for the construction of an anti-human papilloma...
Background: Virus-like Particles (VLPs) display can be used to increase the immunogenicity of hetero...
The currently available nonavalent human papillomavirus (HPV) vaccine exploits the highly antigenic ...
AbstractThe N-terminal region of the human papillomavirus (HPV) L2 protein has been shown to contain...
Human papillomavirus (HPV) capsids are composed of 72 pentamers of the major ...
AbstractAntisera induced by immunization of rabbits with the synthetic peptide P56/75, which has the...
Background: Human papillomavirus (HPV) capsids are composed of 72 pentamers of the major capsid prot...
AbstractNeutralizing antibody against human papillomavirus (HPV) minor capsid protein L2 can cross-n...
Background: Current vaccines against HPVs are constituted of L1 protein self-assembled into virus-li...
Both the Human papillomavirus (HPV) major (L1) and minor (L2) capsid proteins have been well investi...
Abstract Background Current vaccines against HPVs are constituted of L1 protein self-assembled into ...
Abstract Vaccination of mice with minor capsid protein L2 or passive transfer with the L2-specific n...
AbstractCryoelectron microscopy images of HPV16 pseudovirions (PsV) depict that each pentamer of L1 ...
International audienceBACKGROUND: Current vaccines against HPVs are constituted of L1 protein self-a...
Virus-like Particles (VLPs) display can be used to increase the immunogenicity of heterologous antig...
The minor capsid protein L2 is a promising candidate for the construction of an anti-human papilloma...
Background: Virus-like Particles (VLPs) display can be used to increase the immunogenicity of hetero...
The currently available nonavalent human papillomavirus (HPV) vaccine exploits the highly antigenic ...